# MRG-001 in Patients With Amyotrophic Lateral Sclerosis

> **NCT06315608** · PHASE2 · NOT_YET_RECRUITING · sponsor: **MedRegen LLC** · enrollment: 10 (estimated)

## Conditions studied

- Amyotrophic Lateral Sclerosis
- Lou Gehrig Disease
- Motor Neuron Disease
- Motor Neuron Atrophy

## Interventions

- **DRUG:** MRG-001

## Key facts

- **NCT ID:** NCT06315608
- **Lead sponsor:** MedRegen LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-07-01
- **Primary completion:** 2026-01-01
- **Final completion:** 2026-03-01
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2024-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06315608

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06315608, "MRG-001 in Patients With Amyotrophic Lateral Sclerosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06315608. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*